Scipher and Savant Bio Partner to Build the Most Comprehensive Clinico-Genomic Dataset in Rheumatoid Arthritis
The collaboration centers on transforming real-world data from the electronic health records (EHRs) of patients tested with Scipher's clinically validated molecular signature test that predicts non-response to TNF inhibitor therapies, PrismRA ®. These data will be converted into structured, analysis-ready formats. By integrating deep genomic insights with comprehensive clinical context, the partnership aims to generate actionable real-world evidence to accelerate drug development in RA and related autoimmune conditions.
'Enormous potential is locked inside real-world clinical data, but much of it lives in an unstructured form,' said Brian Moriarty, Co-Founder of Savant Bio. 'By linking Scipher's validated genomic insights with structured patient journeys, we are creating the foundation for the next generation of real-world evidence to enable faster studies, richer evidence, and more targeted therapies in RA.'
Savant's platform uses large language models (LLMs), paired with domain-specific quality controls, to extract structured variables from free-text clinical documentation, such as physician notes and pathology reports. Key enriched dimensions include biologic sequencing, disease activity scores (e.g., CDAI, DAS28), steroid exposure, radiographic findings, and treatment durability. Each output undergoes rigorous review to ensure accuracy and consistency and can be linked to claims, labs, and prescribing data for longitudinal analysis.
'As the leader in autoimmune transcriptomic data, we've long believed that combining molecular precision with real-world outcomes is key to advancing drug development in autoimmune disease,' said Reg Seeto, CEO of Scipher Medicine. 'By integrating structured clinical data through Savant's platform, we aim to enhance the utility of the growing Scipher dataset for applications ranging from trial design to market access — and ultimately support more personalized, evidence-driven treatment strategies in autoimmune diseases.'
Initial structuring is underway on a cohort of more than 6,000 PrismRA-tested patients, creating one of the most comprehensive genomically defined RA cohorts with structured EHR data. Additional expansion is planned. The dataset will support critical use cases, including:
Validating real-world predictors of treatment response
Mapping treatment sequencing and disease control
Building precision cohorts for post-TNFi trials
Supporting post-market studies and label expansion
The enriched dataset will be made available through collaborative research initiatives, co-publications, and structured licensing partnerships. Interested organizations are encouraged to engage early to help shape use cases and gain preliminary access to insights.
About Scipher Medicine Scipher Medicine is redefining drug development in autoimmune diseases through its precision diagnostics platform, real-world data, and network biology. The company's Prism ® platform uses genomic signatures to guide therapeutic selection and generate insights into treatment response. Scipher has built the largest genomic biobank in RA, which is coupled with access to EHR data from a network of over 3 million rheumatology patients. Learn more at www.sciphermedicine.com.
About Savant Bio Savant is transforming how healthcare and life sciences organizations unlock the value trapped in unstructured medical data. Its data abstraction platform combines advanced large language models with domain-specific quality controls to convert free-text clinical records into structured, analysis-ready data — efficiently, accurately, and at scale. Backed by Roivant, Savant partners with leading institutions across healthcare, life sciences, and research to deliver sharper insights and better outcomes. Learn more at www.savantbio.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Valens Semiconductor's VA7000 Chipsets Enable the Market's First MIPI A-PHY Platform for Embedded Vision by D3 Embedded
Product suite, including Nvidia processors and Sony sensors, are available for sale on the D3 Embedded website. HOD HASHARON, Israel, July 15, 2025 /PRNewswire/ -- Valens Semiconductor (NYSE: VLN) announced that its chipsets are the keystone connectivity solution for a comprehensive camera-to-processor MIPI A-PHY platform offered by D3 Embedded. The platform brings to market the first product-ready solution for implementing the high-performance A-PHY connectivity standard in embedded vision systems. The A-PHY platform offers D3's customers a series of unique benefits, including unparalleled EMI resilience, longer link distances, and the ability to operate over simple, low-cost cabling. "D3 Embedded's comprehensive camera-to-processor platform is a practical, ready-to-deploy solution that significantly lowers the barrier to entry for companies looking to adopt A-PHY in their embedded vision systems," said Gili Friedman, Head of the Cross-Industry Business Unit at Valens Semiconductor. "Valens sees significant demand for MIPI A-PHY in this market, and we look forward to seeing how this collaboration between our companies will lead to broad adoption of A-PHY, changing the way embedded vision and AI systems are deployed across industries." "A-PHY's ability to deliver high-speed data over long distances with exceptional electromagnetic compatibility is a game-changer for the industry," said Scott Reardon, CEO of D3 Embedded. "Investing in this technology was crucial because it addresses the key challenges our customers face - reliable connectivity in harsh environments and simplified system design, including the industry's first ever use of Unshielded Twisted Pair (UTP) channels for multi-gig use cases. By building this platform around MIPI A-PHY and partnering with Valens Semiconductor, we're giving developers a powerful, flexible toolset to accelerate innovation in embedded vision." On the compute side of the platform, D3 Embedded is offering an NVIDIA® Jetson Orin™ processor (NX or Nano) and 8 A-PHY input ports. The platform has an option for an industrial, fanless enclosure, while each port operates at 8Gbps (7.2Gbps net). On the camera side, D3 Embedded is offering six A-PHY DesignCore® Discovery Series SKUs, all based on the Sony ISX031 sensor. Each camera is offered with an option for a ruggedized IP69K enclosure for the highest level of protection against dust, liquid, and chemicals. The IP69K camera features a removable, anti-reflective coated, and scratch-resistant lens cover for use in harsh environments. D3 Embedded can also develop custom cameras based on other sensors upon customer request. Explore D3 Embedded's A-PHY camera offerings here: The MIPI A-PHY standard delivers outstanding Electromagnetic Compatibility (EMC) performance, ensuring reliable data transmission even in electrically noisy industrial environments. In addition, chipsets based on A-PHY technology enable high-speed data transmission over long cables - up to 30 meters and beyond - without degrading signal quality. These chips also support multi-gig connectivity over both Unshielded Twisted Pair (UTP) and micro-coaxial cabling, giving system designers the flexibility to balance cost, weight, and mechanical requirements according to their specific application needs. Finally, chipsets based on A-PHY offer built-in advanced diagnostics for link monitoring and preventive maintenance, ensuring 24/7 system operation. These advantages make A-PHY-based chipsets ideal for a wide range of applications, including robotics/AMR, industrial vehicles, industrial automation, and medical imaging, where long-reach, high-performance, and cost-effective connectivity is essential. About Valens Semiconductor Valens Semiconductor (NYSE:VLN) is a leader in high-performance connectivity, enabling customers to transform the digital experiences of people worldwide. Valens' chipsets are integrated into countless devices from leading customers, powering state-of-the-art audio-video installations, next-generation videoconferencing, and enabling the evolution of ADAS and autonomous driving. Pushing the boundaries of connectivity, Valens sets the standard everywhere it operates, and its technology forms the basis for the leading industry standards such as HDBaseT® and MIPI A-PHY. For more information, visit About D3 Embedded D3 Embedded is a U.S.-based company that develops end-to-end solutions integrating sensors, connectivity, embedded processing and AI to deliver advanced perception for performance-critical applications. Using its proven DesignCore® product platforms and stage-gate development process, D3 Embedded helps its customers minimize the cost, schedule, and technical risks of product development for performance-critical applications. D3 Embedded is an Elite member of the NVIDIA Partner Network, an Intel Gold Partner, and a premium member of Texas Instruments' third-party network. The company holds expertise in autonomous machines and robotics, electrification, sensing, imaging and optics, edge computing and detection algorithms. To support its products and services, the company offers ODM customization of hardware and software, validation testing and in-house manufacturing services. Learn more at Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding our anticipated future results, including financial results, our five-year plan, currency exchange rates, and contract wins, and future economic and market conditions. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Valens Semiconductor's ("Valens") management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Valens Semiconductor. These forward-looking statements are subject to a number of risks and uncertainties, including the cyclicality of the semiconductor industry; the effect of inflation and a rising interest rate environment on our customers and industry; the ability of our customers to absorb inventory; competition in the semiconductor industry, and the failure to introduce new technologies and products in a timely manner to compete successfully against competitors; if Valens fails to adjust its supply chain volume due to changing market conditions or fails to estimate its customers' demand; disruptions in relationships with any one of Valens' key customers; any difficulty selling Valens' products if customers do not design its products into their product offerings; Valens' dependence on winning selection processes; even if Valens succeeds in winning selection processes for its products, Valens may not generate timely or sufficient net sales or margins from those wins; sustained yield problems or other delays or quality events in the manufacturing process of products; our ability to effectively manage, invest in, grow, and retain our sales force, research and development capabilities, marketing team and other key personnel; our ability to timely adjust product prices to customers following price increase by the supply chain; our ability to adjust our inventory level due to reduction in demand due to inventory buffers accrued by customers; our expectations regarding the outcome of any future litigation in which we are named as a party; our ability to adequately protect and defend our intellectual property and other proprietary rights; our ability to successfully integrate or otherwise achieve anticipated benefits from acquired businesses; the market price and trading volume of the Valens ordinary shares may be volatile and could decline significantly; global political and economic uncertainty, including with respect to China-Taiwan relations; political, economic, governmental and tax consequences associated with our incorporation and location in Israel; and those factors discussed in Valens' Form 20-F filed with the SEC on February 26, 2025 under the heading "Risk Factors," and other documents of Valens filed, or to be filed, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Valens does not presently know or that Valens currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Valens' expectations, plans or forecasts of future events and views as of the date of this press release. Valens anticipates that subsequent events and developments may cause Valens' assessments to change. However, while Valens may elect to update these forward-looking statements at some point in the future, Valens specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Valens' assessment as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Press Contacts Yoni DayanHead of CommunicationsValens Semiconductor Hadley McKinnonSenior Account ExecutiveFusion Investor Contacts Michal Ben AriInvestor Relations ManagerValens Semiconductor Photo: View original content to download multimedia: SOURCE Valens Semiconductor Sign in to access your portfolio
Business Wire
17 minutes ago
- Business Wire
8x8, Inc. Schedules First Quarter Fiscal 2026 Earnings Release and Conference Call
CAMPBELL, Calif.--(BUSINESS WIRE)-- 8x8, Inc. (NASDAQ: EGHT), the industry's most integrated platform provider for CX that combines Contact Center, Unified Communication, and CPaaS solutions, will release financial results for the first fiscal quarter ended June 30, 2025 following the close of market on Tuesday, August 5, 2025. The company will host a conference call on the same day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results. The conference call will last approximately 60 minutes. An audio archive of the webcast will be available on the investor relations events and presentation page for 90 days following the live call. 8x8, Inc. (NASDAQ: EGHT) connects people and organizations through seamless communication on the industry's most integrated platform for Customer Experience – combining Contact Center, Unified Communication, and CPaaS solutions. The 8x8® Platform for CX integrates AI at every level to enable personalized customer journeys, drive operational excellence and insights, and facilitate team collaboration. We help customer experience and IT leaders become the heartbeat of their organizations, empowering them to unlock the potential of every interaction. For additional information, visit or follow 8x8 on LinkedIn, X, and Facebook. Copyright 8x8, Inc. 8x8® is a trademark of 8x8, Inc. All rights reserved.
Associated Press
18 minutes ago
- Associated Press
Radiodetection and UTTO Elevate Utility Locating with Integrated Field Intelligence
BRISTOL, England, July 14, 2025 (SEND2PRESS NEWSWIRE) — UTTO's Locate Assurance® now integrates into Radiodetection's Locate Performance Management™, delivering advanced data-driven solutions and driving the industry forward. This strategic collaboration delivers real-time quality checks, in-depth data analysis and highly accurate mapping for utility locators. The unique system verifies, tracks and manages every locate, leading to improved accuracy, validated mapping and a proactive approach to preventing damages. Suitable for organizations with teams that require data-driven insights, this integration builds confidence in the field, recognizes top performance, and supports critical field work. Key Benefits for Users: Executive Perspective 'This integration marks a pivotal moment for the industry,' says Tom Turner, Radiodetection's Product Management & Marketing Director. 'By integrating Radiodetection's trusted locating technology with UTTO's advanced analytics, customers can go beyond locating buried infrastructure – they can now validate locate quality in real time, reduce risk, and drive smarter field decisions. This is what the future of damage prevention looks like.' Alan Haddy, CEO of UTTO, adds: 'We're not just giving technicians better tools – we're creating a support system that helps technicians succeed every day, building skills, increasing locate precision and feeling empowered in their role. This is how we move the damage prevention industry forward.' Availability The enhanced system will be available to new and existing Locate Performance Management customers in the coming weeks. More details on features and launch timing will follow soon. Looking Ahead This technical collaboration is just the beginning. Radiodetection and UTTO are committed to ongoing innovation and plan to deliver further exciting solutions to the locating and mapping industry, continuing to set new benchmarks for precision, efficiency, and safety in underground infrastructure management. About Radiodetection: Radiodetection is a global leader in developing and supplying innovative test equipment for locating and inspecting underground infrastructure. Its products help utilities, contractors, 811 technicians and professionals worldwide improve safety, reduce costs and enhance operational efficiency. About UTTO: UTTO is a U.S.-based tech pioneer offering enterprise digital solutions for underground damage prevention and surveying, with advanced mapping, quality assurance, and immersive VR training tools. Learn more at Contact: Alberto Iaccarino, Radiodetection – Product Manager, [email protected], Wendy Hart, Radiodetection – Marketing Manager, [email protected], Annie Burns, UTTO – SVP Strategic Alliance & Behavioral Psychology, [email protected] Locate Assurance is a registered trademark of UTTO. LOGO link for media: NEWS SOURCE: UTTO Inc. Keywords: Construction and Building, Locate Assurance, Utility Locating, accurate mapping for utility locators, survey, GNSS Integration, UTTO Inc, BRISTOL, England This press release was issued on behalf of the news source (UTTO Inc.) who is solely responsibile for its accuracy, by Send2Press® Newswire. Information is believed accurate but not guaranteed. Story ID: S2P127700 APNF0325A To view the original version, visit: © 2025 Send2Press® Newswire, a press release distribution service, Calif., USA. RIGHTS GRANTED FOR REPRODUCTION IN WHOLE OR IN PART BY ANY LEGITIMATE MEDIA OUTLET - SUCH AS NEWSPAPER, BROADCAST OR TRADE PERIODICAL. MAY NOT BE USED ON ANY NON-MEDIA WEBSITE PROMOTING PR OR MARKETING SERVICES OR CONTENT DEVELOPMENT. Disclaimer: This press release content was not created by nor issued by the Associated Press (AP). Content below is unrelated to this news story.
